Enzymatic macrocyclization of 1,2,3-triazole peptide mimetics by Oueis, Emilia et al.
COMMUNICATION          
 
 
 
 
Enzymatic macro-cyclization of 1,2,3-triazole peptide mimetics 
Emilia Oueis,[a] Marcel Jaspars,[c] Nicholas J. Westwood,[a] and James H. Naismith*[a][b] 
Dedication ((optional)) 
Abstract: The macrocyclization of linear peptides is very often 
accompanied by significant improvements in their stability and 
biological activity. Many strategies are available for their chemical 
macrocyclization, however, enzyme-mediated methods remain of 
great interest in terms of synthetic utility. To date, known 
macrocyclization enzymes have been shown to be active on both 
peptide and protein substrates. Here we show that the 
macrocyclization enzyme of the cyanobactin family, PatGmac, is 
capable of macrocyclizing substrates with one, two, or three anti-
1,2,3-triazole moieties. The introduction of non-peptidic scaffolds 
into macrocycles is highly desirable in tuning the activity and 
physical properties of peptidic macrocycles. We have isolated and 
fully characterized nine non-natural triazole-containing cyclic 
peptides, a further ten molecules are also synthesized. PatGmac 
has now been shown to be an effective and versatile tool for the 
ring closure by peptide bond formation. 
Macrocycles in general and peptidic macrocycles in particular 
have recently gained more attention since they have been 
identified as potential sources for novel therapeutics.[1] These 
compounds, abundant in nature, are known to possess a wide 
range of biological activities.[1-2] They owe their attractiveness to 
having higher structural rigidity and better chemical stability, 
especially against hydrolysis and peptidase activity in the case 
of peptide-based macrocycles.[3] The increased molecular 
weight of these compounds is usually balanced by their 
increased specificity and selectivity towards the targets 
compared to “small” molecules.[4] Patellamides are natural cyclic 
octapeptides that belong to the large family of cyanobactins.[5] 
Their biosynthesis consists of the modification of a long 
precursor peptide via the action of different tailoring enzymes to 
achieve heterocyclization of cysteines, or threonines and serines 
to thiazoline or oxazoline, proteolysis, macrocyclisation, 
epimerization of certain amino acids, oxidation of the 
heterocycles, and in some cases prenylation.[6]  
Although many natural peptidic macrocycles have some side 
chain modifications, (e.g. sugars, prenyl, lipid), it would appear 
that it is relatively rare in nature, to have both amino acids and 
non-peptidic molecules forming the macrocyclic backbone. 
Nonetheless, the synthesis of such compounds would be greatly 
beneficial for complementary SAR studies on different targets.[2b] 
A restriction to the natural amino acid building blocks in these 
cyclic peptides limits the diversity and thus the chemical 
properties and activities that such molecules can possess. A 
partial solution to this problem comes from the use of non-
natural amino acids in biological systems in vivo or in vitro, [7] 
which have already been demonstrated for peptidic 
macrocycles[8] (Figure 2). Hybrid molecules have gained 
significant attention through the use of the so called stapled 
peptides,[9] but in this case, the non-peptidic module tends to be 
chosen to lock the peptide in a specific conformation rather than 
being a key component for activity. 
 
Figure 1. PatGmac macrocylized compounds; a) the natural compound, 
Patellamide D; b, c, d) examples of previously synthesized non-natural cyclic 
compounds;[8a-c] e) this study; n represents the number of triazole units in the 
sequence; the molecule number represents the position of the triazole (Tz) 
moiety/moieties in the core peptide (i.e. Cyclo(-VTzGAGIGFP) is CP1). The 
highlighted heterocycle in grey is C-terminal in the core peptide. The bold 
parts of the molecules represent the non-natural modifications to the core 
peptide. Ahp: 7-aminoheptanoic acid. (Thz): thiazoline heterocycle.  
The ring closure of peptidic macrocycles can be achieved 
either chemically[2b, 10] or enzymatically with a number of distinct 
enzymes known including butelase,[11] POPB,[12] sortase,[13] 
recombinant asparaginyl endopeptidase (AEP),[14] 
thioesterase,[15] and the macrocyclase enzyme (PatGmac) from 
the patellamide family.[8a-c, 16] PatGmac recognizes a C-terminal 
AYD(G) motif located outside the core of the precursor peptide 
substrate and cleaves it to form a water shielded acyl-enzyme 
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intermediate using its catalytic Asp-His-Ser triad.[16] The 
intermediate is then attacked by the free N-terminal amine of the 
core peptide. The substrate must have a thiazoline, oxazoline or 
a proline immediately N-terminal to the (cleaved off) AYD(G) [16] 
motif with no other restrictions on the rest of the core peptide. 
This very broad substrate range has made PatGmac an 
attractive tool for biotransformation (Figure 2). We decided to 
test its ability to macrocyclise substrates in which non-peptidic 
motifs are included in the sequence. We have chosen to 
investigate the incorporation of 1,4-substituted 1,2,3-triazole[17] 
groups into macrocycles.[18] The triazole ring can act as an 
isostere for a trans-amide bond and its synthesis is facile.[19] 
Further the triazole moiety has been incorporated in many 
biologically active compounds as it is thermodynamically and 
physiologically stable.[20] We reasoned therefore this would be a 
suitable test of the versatility of PatGmac by systematically 
incorporating the triazole unit (Tz) at different positions of the 
precursor peptide while varying their number as well. We report 
herein the successful formation (catalyzed by PatGmac) of 
macrocycles containing one, two, and three 1,2,3-triazoles.[21] 
A series of 19 different linear precursor peptides P based on the 
core sequence VGAGIGFP were prepared by standard solid 
phase peptide synthesis using the Fmoc strategy (Supporting 
information, SI). The linear peptides VGAGIGFPAYD-NH2 
consisted of the core sequence modified with one, two, or three 
non-consecutive triazoles and the PatGmac recognition motif 
AYD with an N-terminal amide. The triazoles were generated 
directly on solid phase using a copper (I) catalyzed azide-alkyne 
cycloaddition (CuAAC).[18b] Azido acids 1a-b and 1d were 
synthesized in one step by a diazo transfer reaction[22] (Scheme 
S3).[23] Fmoc protected amino alkynes 2a-c were synthesized in 
five steps starting from the commercial Boc protected amino 
acid. First, the Weinreb amides were synthesized by a standard 
coupling reaction. The use of DIBAL-H for the amide reduction 
in a one pot procedure with the Bestmann-Ohira reagent[24] in 
our hands was found to yield very little conversion to the 
aldehyde. Separating the two steps with the reduction to 
aldehyde using LiAlH4 followed by the Bestmann-Ohira reagent, 
successfully afforded the Boc protected amino alkynes. A final 
deprotection and protection step afforded the desired alkynes 
2a-c in moderate yields overall (Scheme S4). The N-terminal 
azide was attached on the growing peptide by a standard 
coupling reaction then was subjected to the CuAAC reaction 
with the corresponding alkyne counterpart 2 on solid phase 
(Scheme 1; Scheme S1). Final precursor peptides P1-6 have a 
single triazole (Tz) at a different position of the core 
sequence[25] (the number denoting the position), precursors 
P13-16, P24-26, P35-36 and P46 have two triazoles (i.e. at 
positions 1 and 3 of the peptide for P13; VTzGATzGIGFPAYD), 
and P135 and P246 have three triazoles (Table S1; Table S2). 
P0 has no triazoles and was synthesized to serve as a control 
for the macrocyclization reaction. 
All precursor peptides P were subjected to the macrocylization 
reaction conditions in the presence of PatGmac in bicine buffer 
at pH 8.1 and 37 °C. The reaction progress was monitored by 
MALDI-MS and some of the resulting spectra are shown in 
Figure 3.  
 
Scheme 1. Schematic synthesis of triazole-containing cyclic peptides. 
All 19 precursor peptides converted to the desired macrocyclic 
structure and no significant linear product (AYD cleavage 
product) was detected in the reaction mixture. We observed that 
two triazole-containing substrates were slower to macrocyclize 
than single triazole-containing peptides and that both three 
triazole peptides were the slowest to convert. Nonetheless, 
because PatGmac is known to be a slow enzyme (reactions 
were monitored 20 to 25 days for full conversion on large 
scale).[16] 
Nine of the precursor peptides, P0, P1, P2, P3, P4, P5, P6, P13 
and P135, were reacted at a larger scale (8 µM, 9-10 mg) in the 
presence of PatGmac under the previously stated conditions in 
order to provide sufficient amounts of the macrocyclic product 
for full characterization. Cyclic peptides CP were extracted and 
HPLC purified to afford moderate yields of high purity samples. 
Results are summarized in Tables 1 and S3 (see Scheme 1 or 
SI, section I for structures). For some of these (CP3, CP13, 
CP135), two peaks on the HPLC had the expected mass of the 
cyclic peptide in the crude reaction mixture, as can be seen from 
the ratio column in Table 1 (SI, section VIII). When applicable, 
both peaks were collected and analyzed by HRMS and MS-MS 
fragmentation patterns and both were determined to be the 
desired cyclic peptide (Table S3). However, the NMR 
experiments were only conducted for the major isolated 
compound. 
The MS-MS fragmentation data of the cyclic peptides gave a 
very complex series of ions consistent with their peptidic 
sequence, the newly formed Valine to Proline bond (macrocycle 
formation), and the triazole presence (SI, section VII). 
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Figure 2 MALDI-MS traces of the macrocyclization reactions of representative sequences with a) control peptide; VGAGIGFP, 0 triazole, 20 days; b) 
VTzGAGIGFP, 1 triazole, 21 days; c) VTzGATzGIGFP, 2 triazoles, 23 days; d) VTzGATzGITzGFP, 3 triazoles, 25 days..
NMR experiments were also conducted in order to further 
confirm their structures. The proton NMR data of the cyclic 
peptides showed at least two species present at different ratios 
depending on the compound. For CP0, CP1, CP2, CP3 CP4, 
CP6 and CP13 this was shown by Exchange Spectroscopy 
(EXSY) experiments to result from different conformers (SI, 
section VI). However, compound CP5 was found to have two 
distinct compounds in a 1:0.6 ratio. The NMR assignments of 
both species show they have the same peptidic sequence (cyclic 
VGAGITzGFP). Both HRMS and MS-MS fragmentation data 
confirm the presence of one mass/one sequence. This led us to 
believe that the two species are most likely epimers but we 
cannot exclude structurally rigid conformers unable to 
interconvert.[26] 
Table 1. PatGmac macrocylization reaction products. 
Peptide  Core peptide [a] Ratio 
(%)[b] 
Yield 
(%)[c]  
Purity 
(%)[d] 
CP0 VGAGIGFP 100 32 99 
CP1 VTzGAGIGFP 100 43 99 
CP2 VGTzAGIGFP 100 48 91 
CP3 VGATzGIGFP 76/24 55 99 
CP4 VGAGTzIGFP 100 34 98 
CP5 VGAGITzGFP 100 58 93 
CP6 VGAGIGTzFP 100 40 98 
CP13 VTzGATzGIGFP 20/80 54 98 
CP135 VTzGATzGITzGFP 15/85 39 97 
[a] Tz = triazole replacing the amide bond. [b] Ratio of cyclic products in 
crude mixture (SI, section VIII). [c] Total yield. [d] Purity of major product 
determined by HPLC, UV absorption at 220 nm (SI, section IX). 
CP135 has a very complex proton and 2D NMR spectra that 
showed at least four different species (with two other minor 
species). General assignment has been achieved for most 
proton peaks (SI, section V) however, the individual sequence 
for each was not determined. EXSY showed that two of them 
are related conformers and the other two are distinct compounds. 
Similarly to compound CP5, these species would most probably 
arise from epimers or from conformationally rigid variants. 
Biotransformation is now widely used in organic chemistry 
for the synthesis of biologically relevant compounds. The 
PatGmac enzyme is unusual in that it operates on substrates 
and disposes of almost the entire recognition site during the 
reaction. PatGmac macrocyclizes a wide range of natural 
peptidic substrates and tolerates non-natural amino acids[8a, 8b]. 
From a chemical diversity point of view, the ability to mix amino 
acid residues and non-amino acid scaffolds within the backbone 
of macrocyles is highly desirable. We have now shown that it is 
possible to synthesize macrocycles with one, two, or three 
triazoles within a peptidic sequence. Thus PatGmac is able to 
process peptide hybrid substrates extending its utility. The ability 
to macrocyclise such hybrid molecules highlights the scope for 
creating highly diverse libraries through split and pool 
approaches.  
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The macrocyclase enzyme PatGmac from the patellamide 
pathway of the cyanobactin family successfully macrocyclized 
non-natural precursor peptides where one, two, or three 1,4-
substituted 1,2,3-triazole rings were incorporated at different 
positions of the core peptide. 19 cyclic peptides were 
macrocyclized by PatGmac, among which 9 were isolated and 
fully characterized. PatGmac is proving itself as a versatile tool for 
the macrocyclization of hybrid peptides. 
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